AGENUS INC

AGEN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-3.1M $-232.3M $-257.4M $-230.7M $-28.7M $-182.9M $-111.6M $-162.0M
Depreciation & Amortization $10.0M $13.3M $13.6M $6.9M $6.8M $7.2M $6.7M $6.3M
Depreciation $9.7M $12.8M $11.9M $4.7M $4.6M $5.1M $4.8M $4.3M
Amortization $300.0K $500.0K $1.5M $2.2M $2.1M $2.4M $2.0M $2.0M
Stock-Based Compensation $13.8M $17.4M $22.9M $18.3M $19.6M $10.4M $9.9M $7.6M
Net Cash from Operating Activities $-77.2M $-158.3M $-224.2M $-175.4M $10.1M $-139.1M $-18.7M $-131.1M
Investing Activities
Capital Expenditures $6.0K $576.0K $10.0M $53.1M $33.8M $3.5M $4.7M $3.6M
Business Acquisitions $2.9M $975.0K
Net Cash from Investing Activities $1.2M $27.0K $3.4M $-33.6M $-43.2M $-4.4M $-4.7M $-3.6M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $36.6M $122.8M $119.9M $95.8M $225.3M $183.9M $31.3M $128.3M
Net Change in Cash $-39.4M $-35.7M $-101.6M $-113.3M $207.1M $38.1M $8.8M $-7.1M
Free Cash Flow $-77.2M $-158.9M $-234.2M $-228.4M $-23.7M $-142.6M $-23.3M $-134.7M
← Newer Page 1 of 3 Older →
Peter Lynch

When you sell in desperation, you always sell cheap.